GO:0004767 sphingomyelin phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004767 (sphingomyelin phosphodiesterase activity) catalyzes the hydrolysis of sphingomyelin into ceramide, choline phosphate, and H+, a reaction that generates the bioactive lipid ceramide.
• The term covers both acid and neutral sphingomyelinases, including the lysosomal enzyme deficient in Niemann-Pick disease types A/B (SMPD1) and neutral enzymes such as SMPD2/SMPD3.
• Sphingomyelin phosphodiesterase activity is central to membrane sphingolipid remodeling, ceramide-enriched domain formation, and stress-induced signaling.
• Dysregulated activity is linked to steatohepatitis, glioblastoma metabolism, Niemann-Pick disease, viral restriction of cGAS-STING signaling, and insulin-resistant skeletal muscle.
• SMPDL3B, a related sphingomyelin phosphodiesterase, restricts cGAS-STING signaling by degrading cGAMP and is essential for TLR3 signaling in podocytes.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal dissection of sphingomyelin phosphodiesterase genes in disease and immunity.
Description
Sphingomyelin phosphodiesterase activity (GO:0004767) is a molecular function that hydrolyzes sphingomyelin to produce ceramide, choline phosphate, and a proton. This reaction is a principal route for generating ceramide, a bioactive sphingolipid that organizes membrane domains and transduces stress signals. Because sphingomyelin is a major component of plasma and organelle membranes, its enzymatic cleavage reshapes membrane order and downstream signaling. The function is encoded by a family of enzymes with distinct pH optima and subcellular localizations, including acid sphingomyelinase (SMPD1) and neutral sphingomyelinases such as SMPD2 and SMPD3. Researchers study GO:0004767 to understand lipid-driven disease mechanisms, including Niemann-Pick disease, metabolic liver disease, cancer metabolism, and innate immune regulation. The activity also participates in exercise adaptation and mitochondrial quality control in skeletal muscle. As a result, sphingomyelin phosphodiesterase activity sits at the intersection of membrane biology, lipid signaling, and human disease.
sphingomyelin phosphodiesterase activity At A Glance
| GO ID | GO:0004767 |
|---|---|
| GO term | sphingomyelin phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | sphingomyelinase activity; sphingomyelin cholinephosphohydrolase activity |
| Definition | Catalysis of the reaction: H2O + sphingomyelin = ceramide + choline phosphate + H+ |
| Major function | Hydrolysis of sphingomyelin to generate ceramide and choline phosphate |
| Representative enzymes | SMPD1 (acid), SMPD2/SMPD3 (neutral), SMPDL3B |
| Subcellular context | Lysosomes, plasma membrane, and other membrane compartments |
| Pathological relevance | Niemann-Pick disease, steatohepatitis, cancer metabolism, innate immunity |
What Is GO:0004767?
GO:0004767 describes the catalysis of the reaction H2O + sphingomyelin = ceramide + choline phosphate + H+. In other words, it is the enzymatic activity that cleaves the phosphodiester bond of sphingomyelin, releasing the lipid ceramide and the water-soluble headgroup choline phosphate. The term is synonymous with sphingomyelinase activity and sphingomyelin cholinephosphohydrolase activity. It is classified as a molecular_function in the Gene Ontology and is distinct from ceramidase or sphingomyelin synthase activities, which catalyze different reactions.
Why Is sphingomyelin phosphodiesterase activity Important in Cell Biology?
Sphingomyelin phosphodiesterase activity is important because it controls the balance between sphingomyelin and ceramide, two lipids with opposing roles in membrane organization and cell fate. Ceramide produced by this activity can coalesce into ceramide-enriched membrane domains that cluster receptors and amplify stress signals. Genetic loss of acid sphingomyelinase causes Niemann-Pick disease types A/B, a lysosomal storage disorder with visceral and neurological involvement. In the liver, sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. In cancer, targeting sphingomyelinase-related metabolism affects glioblastoma signaling and growth. In immunity, SMPDL3B restricts cGAS-STING signaling by degrading cGAMP, linking this activity to antiviral defense. In skeletal muscle, exercise training increases sphingomyelinase activity and influences mitochondrial quality control in type 2 diabetes. Together, these findings make GO:0004767 a high-value target for mechanistic and therapeutic research.
• Generates ceramide, a central bioactive lipid in stress, apoptosis, and membrane signaling.
• Deficiency of acid sphingomyelinase (SMPD1) causes Niemann-Pick disease types A/B.
• SMPD3 promotes steatohepatitis by disrupting hepatic membrane sphingolipid metabolism.
• Sphingomyelinase-related metabolism is a targetable vulnerability in glioblastoma.
• SMPDL3B restricts cGAS-STING signaling via cGAMP degradation during viral infection.
• SMPDL3B is essential for Toll-like receptor 3 signaling in human podocytes.
• Exercise training increases skeletal muscle sphingomyelinases and affects mitochondrial quality control in type 2 diabetes.
• Neutral sphingomyelinase activity is a distinct, membrane-associated regulator of ceramide production.
• The activity is a biomarker and mechanistic node in lysosomal storage, metabolic, and immune disorders.
• CRISPR models enable causal testing of sphingomyelin phosphodiesterase genes in disease.
What Happens During sphingomyelin phosphodiesterase activity?
Substrate recognition and membrane access
In simple terms: The enzyme must find sphingomyelin inside a membrane before it can cut it.
Sphingomyelin phosphodiesterases act on sphingomyelin embedded in lipid bilayers, and their access to substrate depends on membrane composition and localization. Ceramide-enriched membrane domains can form after sphingomyelin hydrolysis, creating platforms that concentrate signaling proteins. Neutral sphingomyelinase activity is associated with membrane fractions and is distinct from the lysosomal acid enzyme. In hepatocytes, sphingomyelin phosphodiesterase 3 disrupts membrane sphingolipid metabolism, indicating that substrate access and membrane remodeling are coupled.
Catalytic hydrolysis of sphingomyelin
In simple terms: Water is used to split sphingomyelin into ceramide and choline phosphate.
The catalytic reaction consumes water and cleaves the phosphodiester bond of sphingomyelin, yielding ceramide, choline phosphate, and H+. This reaction is the defining biochemical activity of GO:0004767 and is shared by acid and neutral sphingomyelinases. The acid enzyme SMPD1 is deficient in Niemann-Pick disease types A/B, confirming its role in sphingomyelin catabolism. Neutral sphingomyelinase activity has been biochemically characterized as a distinct membrane-associated activity.
Ceramide generation and membrane domain formation
In simple terms: The ceramide produced can cluster into patches that change how membranes signal.
Ceramide generated by sphingomyelin phosphodiesterase activity can self-associate into ceramide-enriched membrane domains that alter membrane order and protein sorting. These domains are implicated in receptor clustering and stress signaling. In steatohepatitis, hepatic sphingomyelin phosphodiesterase 3 promotes disease by disrupting membrane sphingolipid metabolism, consistent with a role for ceramide in membrane-driven pathology. In glioblastoma, targeting sphingomyelinase-related metabolism affects signaling and metabolic networks.
Downstream signaling and immune modulation
In simple terms: The products of this reaction can turn cell signals on or off, including immune alarms.
SMPDL3B, a sphingomyelin phosphodiesterase, restricts cGAS-STING signaling by degrading cGAMP during viral infection, linking this activity to innate immune control. SMPDL3B is also essential for Toll-like receptor 3 signaling in human podocytes, showing context-dependent signaling roles. In skeletal muscle, exercise training increases sphingomyelinase activity and affects mitochondrial quality control in men with type 2 diabetes. These examples show that sphingomyelin phosphodiesterase activity is not merely catabolic but also a signaling regulator.
Key Genes Involved in GO:0004767 sphingomyelin phosphodiesterase activity
The following genes encode enzymes or related proteins with sphingomyelin phosphodiesterase activity or direct roles in its biology.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SMPD1 | Acid sphingomyelinase; lysosomal sphingomyelin hydrolysis | Deficient in Niemann-Pick disease types A/B |
| SMPD2 | Neutral sphingomyelinase | Membrane-associated ceramide generation |
| SMPD3 | Neutral sphingomyelinase 2 | Promotes steatohepatitis via membrane sphingolipid disruption |
| SMPD4 | Neutral sphingomyelinase family member | Sphingomyelin phosphodiesterase family biology |
| SMPDL3A | Acid-like sphingomyelin phosphodiesterase | Related enzyme with lipid signaling roles |
| SMPDL3B | Sphingomyelin phosphodiesterase acid-like 3b | Restricts cGAS-STING via cGAMP degradation; TLR3 signaling |
| CERK | Ceramide kinase | Ceramide pathway node downstream of sphingomyelin hydrolysis |
| ASAH1 | Acid ceramidase | Ceramide catabolism downstream of sphingomyelin phosphodiesterase |
| SGMS1 | Sphingomyelin synthase 1 | Opposing enzyme that consumes ceramide to make sphingomyelin |
| SGMS2 | Sphingomyelin synthase 2 | Opposing enzyme in sphingomyelin/ceramide balance |
| CERS2 | Ceramide synthase 2 | Ceramide generation pathway |
| CERS6 | Ceramide synthase 6 | Ceramide generation pathway |
| ACER1 | Alkaline ceramidase | Ceramide turnover |
| ACER2 | Alkaline ceramidase | Ceramide turnover |
| ACER3 | Alkaline ceramidase | Ceramide turnover |
| UGCG | Glucosylceramide synthase | Glycosphingolipid branch from ceramide |
| SPTLC1 | Serine palmitoyltransferase subunit | De novo sphingolipid synthesis upstream of sphingomyelin |
| SPTLC2 | Serine palmitoyltransferase subunit | De novo sphingolipid synthesis upstream of sphingomyelin |
How Is sphingomyelin phosphodiesterase activity Regulated?
Sphingomyelin phosphodiesterase activity is regulated at multiple levels, including enzyme abundance, subcellular localization, and membrane lipid environment. Acid sphingomyelinase (SMPD1) is a lysosomal enzyme whose loss causes Niemann-Pick disease, indicating that its activity is tightly linked to lysosomal function. Neutral sphingomyelinase activity is membrane-associated and biochemically distinct, suggesting compartment-specific regulation. In liver, sphingomyelin phosphodiesterase 3 activity disrupts membrane sphingolipid metabolism and promotes steatohepatitis, showing that metabolic stress can shift this activity. In skeletal muscle, exercise training increases sphingomyelinase activity and affects mitochondrial quality control in type 2 diabetes, indicating physiological regulation by exercise. In immunity, SMPDL3B activity is engaged upon viral infection and restricts cGAS-STING signaling, demonstrating stimulus-dependent regulation. SMPDL3B is also required for TLR3 signaling in podocytes, further supporting context-specific control.
sphingomyelin phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SMPD1 | Niemann-Pick disease types A/B | SMPD1 knockout or point-mutation cell model |
| SMPD3 | Steatohepatitis | Hepatocyte SMPD3 knockout and overexpression |
| SMPDL3B | Viral restriction of cGAS-STING; TLR3 signaling | SMPDL3B knockout and tagged knock-in |
| SMPD2 | Neutral sphingomyelinase membrane biology | SMPD2 knockout with lipidomics |
| SMPD1/SMPD3 | Type 2 diabetes skeletal muscle adaptation | Exercise-mimetic overexpression models |
Niemann-Pick disease types A/B
Acid sphingomyelinase deficiency due to SMPD1 mutations causes Niemann-Pick disease types A/B, a lysosomal storage disorder characterized by sphingomyelin accumulation. Clinical, biochemical, and genotype-phenotype correlations in 118 patients show that residual sphingomyelin phosphodiesterase activity influences disease presentation. This establishes GO:0004767 as a direct causal function in a Mendelian disease.
Metabolic liver disease and steatohepatitis
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism. This links GO:0004767 to non-alcoholic steatohepatitis and lipid-driven liver injury. The mechanism involves altered membrane sphingolipid composition and ceramide generation.
Cancer metabolism and glioblastoma
Targeting glioblastoma signaling and metabolism with a repurposed brain-penetrant drug affects sphingomyelinase-related pathways. This suggests that sphingomyelin phosphodiesterase activity contributes to tumor metabolic adaptation. The study highlights the pathway as a therapeutic vulnerability in glioblastoma.
Innate immunity and viral infection
Membrane integrity changes upon viral infection activate sphingomyelinase SMPDL3B to restrict cGAS-STING signaling via cGAMP degradation. SMPDL3B is also essential for Toll-like receptor 3 signaling in human podocytes. These findings position GO:0004767 in antiviral defense and immune regulation.
From sphingomyelin phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SMPD1 reduce acid sphingomyelinase activity? | SMPD1 knockout cell line |
| Does SMPD3 promote steatohepatitis? | Hepatocyte SMPD3 knockout and overexpression |
| How does SMPDL3B restrict cGAS-STING? | SMPDL3B knockout and point-mutation knock-in |
| Is SMPDL3B required for TLR3 signaling? | SMPDL3B knockout podocyte model |
| Does exercise-related sphingomyelinase change mitochondrial quality? | SMPD overexpression in muscle cells |
| Can sphingomyelinase targeting affect glioblastoma metabolism? | SMPD knockout in glioblastoma cells |
How to Study the sphingomyelin phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics | Sphingomyelin and ceramide levels | Confirming GO:0004767 activity changes |
| Enzyme activity assay | Sphingomyelinase catalytic rate | Validating SMPD1/SMPD3 models |
| CRISPR knockout screening | Gene requirement for lipid phenotype | Identifying pathway regulators |
| RNA-seq | Transcriptional changes | Assessing sphingomyelinase gene expression |
| Proteomics | Protein abundance and modifications | Mapping downstream signaling |
| Imaging | Ceramide-enriched membrane domains | Visualizing membrane reorganization |
| Metabolic profiling | Cellular metabolism | Glioblastoma sphingomyelinase targeting |
| Bioinformatics | Pathway and network integration | Prioritizing candidate genes |
Lipidomics and enzyme activity assays
Sphingomyelin phosphodiesterase activity can be measured by quantifying substrate consumption and product formation, including sphingomyelin, ceramide, and choline phosphate. Lipidomics provides a systems-level readout of membrane sphingolipid remodeling. These assays are essential to confirm that a CRISPR model changes GO:0004767 activity.
CRISPR screening and functional genomics
CRISPR knockout screens can identify genes required for sphingomyelin phosphodiesterase-dependent phenotypes such as ceramide generation or immune signaling. Library screening combined with lipid readouts links genotype to lipid phenotype. Bioinformatics analysis of screen hits can nominate pathway nodes for validation.
Imaging and membrane domain analysis
Ceramide-enriched membrane domains can be visualized using lipid probes and imaging to assess membrane organization after sphingomyelin hydrolysis. Imaging of immune signaling complexes can reveal how SMPDL3B modulates cGAS-STING or TLR3 pathways. These methods connect molecular activity to cellular architecture.
Transcriptomics and proteomics
RNA-seq and proteomics can measure expression changes in sphingomyelin phosphodiesterase genes and downstream pathways after perturbation. In skeletal muscle, exercise training increases sphingomyelinase expression and affects mitochondrial quality control, which can be tracked by omics. In cancer, metabolic profiling complements omics to define sphingomyelinase-dependent states.
How CRISPR Can Be Used to Study GO:0004767 sphingomyelin phosphodiesterase activity
Knockout
CRISPR knockout of SMPD1, SMPD3, or SMPDL3B can abolish or reduce sphingomyelin phosphodiesterase activity, enabling causal tests of GO:0004767 in disease models. Knockout of SMPDL3B can reveal its role in cGAS-STING restriction and TLR3 signaling. Hepatocyte SMPD3 knockout can test its contribution to steatohepatitis.
Point Mutation
Point mutations in SMPD1 can model patient variants associated with Niemann-Pick disease types A/B and correlate genotype with residual activity. Point-mutation knock-in of SMPDL3B can dissect catalytic versus non-catalytic functions in immune signaling. These models help distinguish loss-of-function from separation-of-function alleles.
Knock-in
Knock-in of tagged SMPD1 or SMPDL3B allows localization and interaction studies while preserving endogenous regulation. Knock-in of disease-associated variants can recreate human phenotypes in isogenic cell lines. This approach supports precise structure-function analysis of sphingomyelin phosphodiesterase activity.
Overexpression
Overexpression of SMPD3 or SMPDL3B can amplify ceramide generation and downstream signaling, testing sufficiency in disease models. Overexpression in muscle cells can mimic exercise-induced sphingomyelinase increases and mitochondrial effects. Overexpression in glioblastoma cells can test metabolic dependencies.
How EDITGENE Supports sphingomyelin phosphodiesterase activity Research
Researchers studying sphingomyelin phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in ceramide generation, membrane remodeling, or disease phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise perturbation of SMPD1, SMPD2, SMPD3, SMPDL3B, and related genes. By combining knockout, point-mutation, knock-in, overexpression, and library screening, EDITGENE supports mechanistic studies from target validation to functional genomics.
Contact EDITGENE today to design your custom CRISPR model for sphingomyelin phosphodiesterase activity research.
Frequently Asked Questions About sphingomyelin phosphodiesterase activity
What is sphingomyelin phosphodiesterase activity?
It is the enzymatic activity defined by GO:0004767 that catalyzes H2O + sphingomyelin = ceramide + choline phosphate + H+.
What genes are involved in sphingomyelin phosphodiesterase activity?
Key genes include SMPD1, SMPD2, SMPD3, SMPD4, SMPDL3A, and SMPDL3B, which encode acid or neutral sphingomyelinases and related enzymes.
What is the GO ID for sphingomyelin phosphodiesterase activity?
The Gene Ontology ID is GO:0004767, classified under molecular_function.
What reaction does sphingomyelin phosphodiesterase catalyze?
It hydrolyzes sphingomyelin into ceramide, choline phosphate, and H+.
Which disease is caused by SMPD1 deficiency?
SMPD1 deficiency causes Niemann-Pick disease types A/B, a lysosomal storage disorder.
How is sphingomyelin phosphodiesterase activity linked to steatohepatitis?
Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.
Does sphingomyelin phosphodiesterase activity affect immunity?
Yes, SMPDL3B restricts cGAS-STING signaling via cGAMP degradation and is essential for TLR3 signaling in podocytes.
Is sphingomyelin phosphodiesterase activity involved in cancer?
Targeting glioblastoma signaling and metabolism affects sphingomyelinase-related pathways, indicating a role in cancer metabolism.
How can I study sphingomyelin phosphodiesterase activity with CRISPR?
CRISPR knockout, point-mutation, knock-in, and overexpression models can test causal roles of SMPD1, SMPD3, and SMPDL3B.
What methods measure sphingomyelin phosphodiesterase activity?
Lipidomics, enzyme activity assays, imaging of ceramide domains, and omics methods are commonly used.
Conclusion
GO:0004767 sphingomyelin phosphodiesterase activity defines a central lipid-hydrolyzing function that generates ceramide and shapes membrane signaling. Its dysregulation is causally linked to Niemann-Pick disease, steatohepatitis, cancer metabolism, immune regulation, and muscle adaptation. CRISPR-based models provide a rigorous path to test these mechanisms and to identify therapeutic opportunities targeting sphingomyelin phosphodiesterase activity.
References
- 1. Jiang J et al.. 2025. Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism.. Cell Metab 37(5):1119-1136.e13 PMID: 40015281
- 2. Bi J et al.. 2021. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug.. Cell Rep 37(5):109957 PMID: 34731610
- 3. Hu J et al.. 2021. Clinical, biochemical, and genotype-phenotype correlations of 118 patients with Niemann-Pick disease Types A/B.. Hum Mutat 42(5):614-625 PMID: 33675270
- 4. Wang Z et al.. 2025. Membrane integrity changes upon viral infection activate sphingomyelinase SMPDL3B to restrict cGAS-STING signaling via cGAMP degradation.. Immunity 58(11):2670-2684.e10 PMID: 41175872
- 5. Bollinger CR et al.. 2005. Ceramide-enriched membrane domains.. Biochim Biophys Acta 1746(3):284-94 PMID: 16226325
- 6. Hendlinger M et al.. 2025. Exercise training increases skeletal muscle sphingomyelinases and affects mitochondrial quality control in men with type 2 diabetes.. Metabolism 172:156361 PMID: 40759392
- 7. Watanabe S et al.. 2022. Sphingomyelin Phosphodiesterase Acid-Like 3b is Essential for Toll-Like Receptor 3 Signaling in Human Podocytes.. J Membr Biol 255(1):117-122 PMID: 34739556
- 8. Chatterjee S. 1993. Neutral sphingomyelinase.. Adv Lipid Res 26:25-48 PMID: 8379453
